These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11118100)

  • 1. Nondepleting anti-CD4 monoclonal antibody enhances the ability of oral alloantigen delivery to induce indefinite survival of cardiac allografts: oral tolerance to alloantigen.
    Niimi M; Witzke O; Bushell A; Hara M; Morris PJ; Wood KJ
    Transplantation; 2000 Nov; 70(10):1524-8. PubMed ID: 11118100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression.
    Wong W; Morris PJ; Wood KJ
    Transplantation; 1997 May; 63(10):1490-4. PubMed ID: 9175815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of operational tolerance and generation of regulatory cells after intratracheal delivery of alloantigen combined with nondepleting anti-CD4 monoclonal antibody.
    Aramaki O; Shirasugi N; Akiyama Y; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Niimi M
    Transplantation; 2003 Nov; 76(9):1305-14. PubMed ID: 14627908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen.
    Arima T; Lehmann M; Flye MW
    Transplantation; 1997 Jan; 63(2):284-92. PubMed ID: 9020332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration.
    Motoyama K; Arima T; Yu S; Lehmann M; Flye MW
    Transplantation; 2000 Jan; 69(2):285-93. PubMed ID: 10670640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syngeneic bone marrow expressing a single donor class I MHC molecule permits acceptance of a fully allogeneic cardiac allograft.
    Wong W; Morris PJ; Wood KJ
    Transplantation; 1996 Nov; 62(10):1462-8. PubMed ID: 8958273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of alloantigen plus nondepleting anti-CD4 monoclonal antibody induces indefinite prolongation of fully allogeneic cardiac allografts.
    Niimi M; Ikeda Y; Shirasugi N; Shatari T; Takami H; Kodaira S; Matsumoto K; Hamano K; Esato K; Hara M; Wood KJ
    Transplant Proc; 2000 Mar; 32(2):259. PubMed ID: 10715410
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients.
    Hamano K; Rawsthorne MA; Bushell AR; Morris PJ; Wood KJ
    Transplantation; 1996 Sep; 62(6):856-60. PubMed ID: 8824489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway.
    Uchida N; Shirasugi N; Akiyama Y; Matsumoto K; Shimazu M; Kitajima M; Hamano K; Aramaki O; Ikeda Y; Niimi M
    Transplantation; 2003 Mar; 75(6):878-84. PubMed ID: 12660518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral delivery of alloantigen combined with non-depleting anti-CD4 monoclonal antibody induces indefinite survival of cardiac allografts and generates CD4(+) regulatory T cells.
    Niimi M; Ikeda Y; Shirasugi N; Shatari T; Takami H; Kodaira S; Matsumoto K; Hamano K; Esato K; Hara M; Wood KJ
    Transplant Proc; 2000 Nov; 32(7):2035. PubMed ID: 11120054
    [No Abstract]   [Full Text] [Related]  

  • 11. CD27/CD70, CD134/CD134 ligand, and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigen.
    Aramaki O; Shirasugi N; Akiyama Y; Shibutani S; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Okumura K; Yagita H; Niimi M
    Transplantation; 2003 Sep; 76(5):772-6. PubMed ID: 14501851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of hyporesponsiveness to fully allogeneic cardiac grafts by intratracheal delivery of alloantigen.
    Shirasugi N; Ikeda Y; Akiyama Y; Matsumoto K; Hamano K; Esato K; Bashuda H; Yagita H; Okumura K; Takami H; Kodaira S; Niimi M
    Transplantation; 2001 Feb; 71(4):561-4. PubMed ID: 11258436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7/CTLA4 pathway is essential for generating regulatory cells after intratracheal delivery of alloantigen in mice.
    Akiyama Y; Shirasugi N; Uchida N; Matsumoto K; Kitajima M; Bashuda H; Yagita H; Okumura K; Aramaki O; Niimi M
    Transplantation; 2002 Sep; 74(5):732-8. PubMed ID: 12352894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the CTLA4 pathway in hyporesponsiveness induced by intratracheal delivery of alloantigen.
    Shirasugi N; Akiyama Y; Aramaki O; Shibutani S; Matsumoto K; Bashuda H; Yagita H; Okumura K; Ikeda Y; Niimi M
    Transplantation; 2003 May; 75(10):1636-9. PubMed ID: 12777848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of thymus to maintain operational tolerance to fully allogeneic cardiac grafts.
    Niimi M; Shirasugi N; Ikeda Y; Kan S; Takami H; Hamano K
    Ann Thorac Surg; 2001 Sep; 72(3):735-9. PubMed ID: 11565650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (OX-38) with donor antigen administration.
    Motoyama K; Arima T; Lehmann M; Flye MW
    Surgery; 1997 Aug; 122(2):213-9; discussion 219-20. PubMed ID: 9288125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of anti-CD4 monoclonal antibody with intrathymic injection of alloantigen results in rat cardiac allograft tolerance.
    Arima T; Goss JA; Walp LA; Flye MW
    Surgery; 1995 Aug; 118(2):265-72; discussion 272-3. PubMed ID: 7638743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organ transplant specificity of tolerance to skin grafts with heart or kidney grafts plus nondepleting anti-CD4 monoclonal antibody (RIB 5/2) and intravenous donor alloantigen administration.
    Otomo N; Margenthaler JA; Motoyama K; Arima T; Shimizu Y; Lehmann M; Flye MW
    J Surg Res; 2001 Jun; 98(1):59-65. PubMed ID: 11368539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral delivery of xeno-antigen combined with non-depleting anti-CD4 monoclonal antibody induces significantly prolonged survival of concordant skin xenograft.
    Niimi M; Shirasugi N; Hamano K; Esato K; Matsumoto K; Ikeda Y; Shatari T; Takami H; Kodaira S
    Xenotransplantation; 2001 Feb; 8(1):75-9. PubMed ID: 11208193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linked unresponsiveness: early cytokine gene expression profiles in cardiac allografts following pretreatment of recipients with bone marrow cells expressing donor MHC alloantigen.
    Spriewald BM; Billing JS; Ensminger SM; Morris PJ; Wood KJ
    Cytokine; 2002 Jul; 19(1):6-13. PubMed ID: 12200107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.